Opinion | Published:

Efficient drug approval and monitoring must rely on sound regulatory science

Nature Medicine volume 17, page 1535 (2011) | Download Citation

The path to drug approval is long, hard and often perplexing. In recent months, the US Food and Drug Administration (FDA) has promised to bolster 'regulatory science', which aims to transform its decision-making process to be more efficient, transparent and accountable. However, diverse stakeholders, including patients, drug developers and the US Congress, will have to rise to the challenge of coordinating their priorities if this endeavor is to succeed.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Author information

Affiliations

  1. Emma A. Meagher is the director of educational programs at the University of Pennsylvania Perelman School of Medicine in Philadelphia, Pennsylvania, USA.

    • Emma A Meagher
  2. Garret A. FitzGerald is the director of the Institute for Translational Medicine and Therapeutics at the University of Pennsylvania Perelman School of Medicine in Philadelphia, Pennsylvania, USA.

    • Garret A FitzGerald

Authors

  1. Search for Emma A Meagher in:

  2. Search for Garret A FitzGerald in:

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nm1211-1535

Further reading

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing